Effects of combined pioglitazone and metformin on diabetes and obesity in wistar fatty rats

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 4, 2002, Pages 269-274

  Suzuki, Masami ^a   Odaka, Hiroyuki ^a   Suzuki, Noriko ^a   Sugiyama, Yasuo ^a   Ikeda, Hitoshi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Adipose tissue; Diabetes mellitus; Glycogen; Metformin; Obesity; Pioglitazone HCl; Total ketone bodies; Wistar fatty rat

Indexed keywords

GLYCOGEN; KETONE BODY; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCOGEN ANALYSIS; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTRIGLYCERIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RAT; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; EATING; GLYCOGEN; HYPOGLYCEMIC AGENTS; KETONE BODIES; LIVER; MALE; METFORMIN; MUSCLE, SKELETAL; OBESITY; ORGAN SIZE; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036118901     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03644.x     Document Type: Article

References (40)

1. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations
2. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
3. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylurea
4. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
6. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
7. Pioglitazone
8. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
9. A new genetically obese-hyperglycemic rat (Wistar fatty)
10. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals
11. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats
12. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats
13. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase
14. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
15. Pioglitazone in the treatment of type 2 diabetes mellitus: US clinical experience
16. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
17. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
18. PPARγ: Adipogenic regulator and thiazolidinedione receptor
19. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
20. Regulation of PPARγ gene expression by nutrition and obesity in rodents
21. Peroxisome proliferator-activated receptor (PPAR) γ: Adipose-predominant expression and induction early in adipocyte differentiation
22. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
23. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
24. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats
25. Role of metformin in treatment of diabetes mellitus
26. Specific inhibition of gluconeogenesis by biguanides
27. Mechanism of metformin action in non-insulin-dependent diabetes
28. Effect of metformin on insulin receptor binding and glycemic control in type II diabetes
29. Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients
30. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes
31. Cellular mechanisms of action of metformin
32. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
33. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients
34. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
35. Effect of glucose control and weight reduction on postprandial lipid clearance: Animal aspect
36. PPAR3 and PPAR3 activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
37. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes
38. Effect of metformin on food intake in obese subjects
39. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes
40. Effect of chronic metformin treatment on hepatic and muscle glycogen metabolism in KK mice